Next Article in Journal
From A to m6A: The Emerging Viral Epitranscriptome
Next Article in Special Issue
Global Utilization Trends of Direct Acting Antivirals (DAAs) during the COVID-19 Pandemic: A Time Series Analysis
Previous Article in Journal
A Novel Plasmid DNA-Based Foot and Mouth Disease Virus Minigenome for Intracytoplasmic mRNA Production
Previous Article in Special Issue
Hepatitis B Virus-Related Cryoglobulinemic Vasculitis: Review of the Literature and Long-Term Follow-Up Analysis of 18 Patients Treated with Nucleos(t)ide Analogues from the Italian Study Group of Cryoglobulinemia (GISC)
Review

Management and Treatment of Hepatitis C: Are There Still Unsolved Problems and Unique Populations?

1
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20082 Milan, Italy
2
Division of Internal Medicine and Hepatology, Humanitas Research Hospital IRCCS, Rozzano, 20089 Milan, Italy
3
Gastroenterology Unit, Department of Internal Medicine, University of Genoa, IRCCS-Ospedale Policlinico San Martino, 16132 Genoa, Italy
*
Author to whom correspondence should be addressed.
Academic Editors: Pietro Andreone and Stefano Brillanti
Received: 7 April 2021 / Revised: 27 May 2021 / Accepted: 28 May 2021 / Published: 1 June 2021
(This article belongs to the Special Issue Viral Hepatitis Treatment)
Direct-acting antivirals (DAA) have revolutionized the treatment of patients with chronic hepatitis C virus (HCV) infection, possibly leading to HCV elimination by 2030 as endorsed by the World Health Organization (WHO). However, some patients belonging to the so-called unique or special populations are referred to as difficult-to-treat due to unreached sustained virological response, potential drug side effects or interactions or co-morbidities. Several years after the DAA introduction and on the basis of excellent findings in terms of efficacy and safety, some doubts arise around the exact meaning of the special population designation and whether this group of patients actually exists. The aim of this review is to discuss and analyze current evidence on the management and treatment of the so-called “unique populations”. We placed particular emphasis on patients with decompensated cirrhosis, chronic kidney disease (CKD), coinfections, rare genotypes, and previous treatment failure, in order to provide physicians with an updated overview of the actual problems and needs in the current scenario. View Full-Text
Keywords: hepatitis C; unique populations; special populations; decompensated cirrhosis; chronic kidney disease; end stage renal disease; HIV/HBV coinfection; rare genotypes; treatment failure hepatitis C; unique populations; special populations; decompensated cirrhosis; chronic kidney disease; end stage renal disease; HIV/HBV coinfection; rare genotypes; treatment failure
Show Figures

Figure 1

MDPI and ACS Style

Solitano, V.; Plaz Torres, M.C.; Pugliese, N.; Aghemo, A. Management and Treatment of Hepatitis C: Are There Still Unsolved Problems and Unique Populations? Viruses 2021, 13, 1048. https://0-doi-org.brum.beds.ac.uk/10.3390/v13061048

AMA Style

Solitano V, Plaz Torres MC, Pugliese N, Aghemo A. Management and Treatment of Hepatitis C: Are There Still Unsolved Problems and Unique Populations? Viruses. 2021; 13(6):1048. https://0-doi-org.brum.beds.ac.uk/10.3390/v13061048

Chicago/Turabian Style

Solitano, Virginia, Maria C. Plaz Torres, Nicola Pugliese, and Alessio Aghemo. 2021. "Management and Treatment of Hepatitis C: Are There Still Unsolved Problems and Unique Populations?" Viruses 13, no. 6: 1048. https://0-doi-org.brum.beds.ac.uk/10.3390/v13061048

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop